Latest news with #proteomics
National Post
2 days ago
- Business
- National Post
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
Article content MARLBOROUGH, Mass. — SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. Article content Article content The reseller agreement empowers researchers to implement standardized proteomics workflows, delivering a robust LC-MS solution designed to meet the evolving demands of pharmaceutical and biotech companies. With Evosep Eno, researchers gain exceptional throughput, sensitivity, and reproducibility. When combined with SCIEX mass spectrometers—engineered for speed and sensitivity in both quantitative and qualitative analyses—this collaboration ensures access to cutting-edge technology tailored to today's analytical challenges. Article content The latest research from SCIEX and Evosep, shows that the Evosep Eno provides an >5-fold increase of peptide precursor identifications and an >3-fold increase of protein group identifications, at 500 SPD, when coupled to the new ZenoTOF 8600 system. This enables a greater depth of proteome coverage for large-scale cohort, high-throughput analysis. Article content 'For the application of proteomics in translational medicine, this extended collaboration between SCIEX and Evosep will further adoption of standardized solutions and make the technology more accessible—even to those new to proteomics,' said Morten Bern, CEO of Evosep. 'Together, we have an exciting opportunity to make a meaningful impact through LC-MS–based proteomics by combining our strengths to deliver solutions that ultimately enhance patient care and improve quality of life.' Article content 'Our collaboration with Evosep over the years has allowed us to continue to advance and standardize high throughput proteomics workflows. It is exciting to see the exceptional performance for the quantitative identification of peptides and proteins in complex samples. We are committed to providing the best solution for our customers,' said Jose Castro-Perez Ph.D., Vice president of product management at SCIEX. Article content This agreement allows users to access SCIEX mass spectrometry systems and the Evosep Eno via a single product catalogue issued by SCIEX. This option is available to customers located in the USA, Canada, Germany, France, Italy, Switzerland, Austria, Spain, Portugal, Sweden, Norway, Denmark, Finland, Belgium, Netherlands, Latvia, Lithuania, Estonia, and Luxembourg. Both vendors commit to deliver coordinated service and leading analytical performance. SCIEX will support the full customer relationship and Evosep will provide direct UHPLC service and support. Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content
Associated Press
3 days ago
- Health
- Associated Press
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected]
Yahoo
3 days ago
- Health
- Yahoo
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact:Consort Partnerspr@ Investor Contact:Carrie Mendivilinvestor@ in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
